Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series) - Image 1

£60.89

CRC Press Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)

Name: Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)
Brand: CRC Press
Price: 60.89 GBP
Availability: InStock

Allied Health Professions

This is the usual price. Wait for it to drop, or tell us your number.

£61 today · usual range £0–£0 · best ever £54

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 636 days • 636 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 636 days • 6 price levels

Days at Price

Current Price

Price Analysis

Most common price: £54 (224 days, 35.2%)

Price range: £54 - £61

Price levels: 6 different prices over 636 days

Description

Theory of Drug Development presents a formal quantitative framework for understanding drug development that goes beyond simply describing the properties of the statistics in individual studies. It examines the drug development process from the perspectives of drug companies and regulatory agencies. By quantifying various ideas underlying drug development, the book shows how to systematically address problems, such as: Sizing a phase 2 trial and choosing the range of p-values that will trigger a follow-up phase 3 trial Deciding whether a drug should receive marketing approval based on its phase 2/3 development program and recent experience with other drugs in the same clinical area Determining the impact of adaptive designs on the quality of drugs that receive marketing approval Designing a phase 3 pivotal study that permits the data-driven adjustment of the treatment effect estimate Knowing when enough information has been gathered to show that a drug improves the survival time for the whole patient population Drawing on his extensive work as a statistician in the pharmaceutical industry, the author focuses on the efficient development of drugs and the quantification of evidence in drug development. He provides a rationale for underpowered phase 2 trials based on the notion of efficiency, which leads to the identification of an admissible family of phase 2 designs. He also develops a framework for evaluating the strength of evidence generated by clinical trials. This approach is based on the ratio of power to type 1 error and transcends typical Bayesian and frequentist statistical analyses.

Product Specifications

Brand: CRC Press
Format: paperback
ASIN: 1138374687
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Allied Health Professions
Domain: Amazon UK
Release Date: 30 August 2019
Listed Since: 25 November 2018

Barcode

No barcode data available

CRC Press Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)

This is the usual price. Wait for it to drop, or tell us your number.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Theory of Drug Development: 61 (Chapman & Hall/CRC Biostatistics Series)

New Drug Development: An Introduction to Clinical Trials: Second Edition

Statistical Issues in Drug Development (Statistics in Practice)

Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy

Statistics In the Pharmaceutical Industry: 14 (Chapman & Hall/CRC Biostatistics Series)

Quantitative Decisions in Drug Development (Springer Series in Pharmaceutical Statistics)

Quantitative Decisions in Drug Development (Springer Series in Pharmaceutical Statistics)

Fundamentals of Drug Development

Global New Drug Development: An Introduction (ULLA Series in Pharmaceutical Sciences)

Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)

Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials (Chapman & Hall/CRC Biostatistics Series)

Practical Considerations for Adaptive Trial Design and Implementation (Statistics for Biology and Health)

Multiple Testing Problems in Pharmaceutical Statistics (Chapman & Hall/CRC Biostatistics Series)

Multiple Testing Problems in Pharmaceutical Statistics: 33 (Chapman & Hall/CRC Biostatistics Series)

Statistical Methods in Biomarker and Early Clinical Development

Adaptive and Flexible Clinical Trials

Dose Finding in Drug Development (Statistics for Biology and Health)

Statistical Methods in Biomarker and Early Clinical Development

Pharmaceutical Statistics Using SAS: A Practical Guide (SAS Press)

Design and Analysis of Clinical Trials: Concept and Methodologies (Wiley Series in Probability and Statistics)

FDA's Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions

Clinical Trials of Drugs and Biopharmaceuticals

Pharmaceutical Statistics: MBSW 39, Muncie, Indiana, USA, May 16-18, 2016: 218 (Springer Proceedings in Mathematics & Statistics, 218)

Real-World Evidence in a Patient-Centric Digital Era (Chapman & Hall/CRC Biostatistics Series)